Sarcomatoid renal cell carcinoma
Jump to navigation
Jump to search
| Page editor | Section editor | ||
|---|---|---|---|
 |
Teja Ganta, MD Icahn School of Medicine at Mount Sinai New York, NY, USA |
 |
Ali Raza Khaki, MD Stanford University Palo Alto, CA, USA |
Note: these are regimens tested in histology-specific populations, please see the main RCC page for other regimens.
| Last updated on 2024-07-23: 2 regimens on this page
2 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Kidney Cancer.
Metastatic disease, first-line
Doxorubicin & Gemcitabine
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Haas et al. 2012 (ECOG 8802) | 2004-2007 | Phase 2 |
Chemotherapy
- Doxorubicin (Adriamycin) 50 mg/m2 IV push once on day 1
- Gemcitabine (Gemzar) 1500 mg/m2 IV over 30 minutes once on day 1
Supportive therapy
- One of the following:
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 2 or 3, given until day 10
- Pegfilgrastim (Neulasta) 6 mg SC once on day 2
14-day cycle for 6 to 9 cycles (cumulative doxorubicin dose of 300 to 450 mg/m2, depending on cardiac function)
References
- ECOG 8802: Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7. Epub 2011 Feb 6. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT00068393
Gemcitabine & Sunitinib
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Michaelson et al. 2015 (MGH 07-212) | 2007-2013 | Phase 2 |
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
Targeted therapy
- Sunitinib (Sutent) 37.5 mg PO once per day on days 1 to 14
21-day cycles
References
- MGH 07-212: Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. link to original article PubMed NCT00556049